Plus Therapeutics Teams Up with UnitedHealthcare
Plus Therapeutics, Inc. (NASDAQ: PSTV) recently announced an important partnership with UnitedHealthcare Insurance Company, which will significantly enhance patient access to innovative diagnostics in America. The company's subsidiary, CNSide Diagnostics, has secured a national coverage agreement that is expected to benefit over 51 million individuals across the country. This collaboration marks a pivotal step in improving the accuracy of diagnoses for patients suffering from metastatic central nervous system (CNS) cancer.
About the CNSide® Assay
The CNSide® Cerebrospinal Fluid (CSF) Assay is designed to detect tumor cells in the CSF of patients, playing a critical role in diagnosing and monitoring treatment for leptomeningeal metastases. With an impressive clinical utility showcased in multiple peer-reviewed studies and the successful FORESEE clinical trial, this assay offers a reliable solution for healthcare professionals working with cancer patients.
Clinical Evidence and Impact
Since its inception in 2020, more than 11,000 CNSide® tests have been administered across over 120 cancer institutions in the U.S. The assay boasts a remarkable sensitivity of 92% and specificity of 95%, underscoring its effectiveness in clinical settings. Notably, this diagnostic tool has influenced treatment decisions in approximately 90% of cases, demonstrating its vital role in patient management.
Accessibility and Service
Exclusively available through CNSide Diagnostics, this assay service enables healthcare professionals to provide quicker and more accurate treatment plans for their patients. The national coverage from UnitedHealthcare will allow more patients access to this critical testing, enabling timely interventions that can improve clinical outcomes.
About Plus Therapeutics and the Future
Based in Houston, Texas, Plus Therapeutics is at the forefront of developing cutting-edge radiotherapeutics in the fight against challenging central nervous system cancers. With a strong focus on delivering targeted treatments that combine advanced drug delivery techniques with localized radiation therapy, the company is committed to enhancing patient care. Their portfolio includes promising programs aimed at tackling recurrent glioblastoma and leptomeningeal metastases.
About UnitedHealthcare Group
UnitedHealth Group (NYSE: UNH) operates as a leading health care company dedicated to improving health outcomes and simplifying the health care experience for individuals. Its two main divisions, Optum and UnitedHealthcare, work collaboratively to deliver comprehensive health benefits and services that empower patients and providers alike.
Frequently Asked Questions
1. What is the CNSide® Assay?
The CNSide® Assay is a diagnostic test designed to identify tumor cells in cerebrospinal fluid, aiding in the diagnosis and treatment of CNS cancers.
2. How does the partnership with UnitedHealthcare benefit patients?
This partnership enables coverage for the CNSide® Assay, allowing over 51 million people access to crucial testing and diagnosis services.
3. What are the advantages of using the CNSide® Assay?
The assay offers high sensitivity and specificity, which can influence treatment decisions in a majority of cases, leading to better patient management.
4. How many tests have been performed with the CNSide® Assay?
More than 11,000 CNSide® tests have been conducted at over 120 cancer institutions across the U.S. since 2020.
5. What is the role of Plus Therapeutics in cancer treatment?
Plus Therapeutics develops innovative radiotherapeutics to address difficult-to-treat cancers of the CNS, improving therapeutic outcomes through advanced treatment modalities.
